This report presents the case of a germline breast cancer type 1 (BRCA1) mutation carrier patient with TNBC cancer without androgen receptor (AR) expression, and with a HER2 status switch during the course of the disease. This evidence concerns the gene ERBB2 and breast carcinoma.